Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin and Cefixime for Third Molar Surgery Complications
NCT05027893Unknown
- Sponsor
- University of Novi Sad
- Start
- Jun 2019
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial in surgical site infection (SSI) and alveolar osteitis (AO) comparing Moxifloxacin, Cefixime and Placebo (3 arms). Primary endpoint: Rate of postoperative infection at the surgical site at 12 weeks. Status: unknown.
02
Drugs
moxifloxacincefixime
03
Conditions
surgical site infection (SSI)alveolar osteitis (AO)
Beyond the preview
Go deeper on NCT05027893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027893.